Valuation: Isofol Medical AB

Market Cap 248M 25.71M 22.49M 20.74M 19.19M 36.42M 2.45B 37.03M 97.37M 1.21B 96.52M 94.43M 4.17B P/E 2026 *
-4.08x
P/E 2027 * -25.8x
Enterprise Value 146M 15.15M 13.25M 12.22M 11.31M 21.47M 1.45B 21.82M 57.38M 710M 56.88M 55.65M 2.46B EV / Sales 2026 *
-
EV / Sales 2027 * 3.63x
Free-Float
90.89%
Yield 2026 *
-
Yield 2027 * -
1 day+6.97%
1 week+2.35%
Current month+12.64%
1 month+18.77%
3 months+20.67%
6 months+19.19%
Current year+13.72%
1 week 0.76
Extreme 0.756
0.95
1 month 0.68
Extreme 0.675
0.95
Current year 0.55
Extreme 0.5515
0.99
1 year 0.55
Extreme 0.5515
1.18
3 years 0.45
Extreme 0.45
4.88
5 years 0.45
Extreme 0.45
14.44
10 years 0.45
Extreme 0.45
33.5
Manager TitleAgeSince
Chief Executive Officer 74 2024-01-08
Director of Finance/CFO 60 2024-08-12
Chief Executive Officer 61 2023-06-21
Director TitleAgeSince
Chairman 85 2010-06-30
Director/Board Member 76 2017-12-31
Director/Board Member 78 2024-01-03
Date Insider Type Main position Quantity % Market Cap.
21-12-09Sell 58,767 0.0364%
21-12-09Sell 58,767 0.0364%
21-06-13
Healthcom GmbH
BuyCompany 233,336 0.2239%
Change 5-day change 1-year change 3-year change Capi.($)
+6.45%+2.35%-8.45%+31.38% 25.71M
-0.73%-3.47%+49.41%+14.74% 309B
+0.79%-3.09%+23.33%-3.22% 69.38B
-2.18%-1.04%+38.95%+114.69% 9.33B
-1.23%-0.84%+6.26%+1.52% 8.62B
-2.31%-7.39%-14.50%+6.37% 4.16B
+4.55%-3.54%+11.70%+24.63% 4.01B
-2.46%-3.85%-38.28%+24.81% 3.33B
-3.35%+1.46%+49.22%+64.47% 2.83B
+0.28%-5.70%+9.56%-24.42% 2.09B
Average +0.12%-2.29%+12.72%+25.50% 41.27B
Weighted average by Cap. +0.14%-0.63%+41.96%+13.94%

Financials

2026 *2027 *
Net sales - 43.33M 4.49M 3.92M 3.62M 3.35M 6.35M 428M 6.46M 16.99M 210M 16.84M 16.47M 728M
Net income -61.25M -6.34M -5.55M -5.11M -4.73M -8.98M -605M -9.13M -24.01M -297M -23.8M -23.29M -1.03B -40.15M -4.16M -3.64M -3.35M -3.1M -5.89M -397M -5.99M -15.74M -195M -15.6M -15.26M -675M
Net Debt -102M -10.56M -9.24M -8.52M -7.88M -14.96M -1.01B -15.21M -39.98M -495M -39.64M -38.78M -1.71B -91M -9.42M -8.24M -7.6M -7.03M -13.34M -899M -13.57M -35.67M -442M -35.36M -34.6M -1.53B
Logo Isofol Medical AB
Isofol Medical AB is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company’s main shareholders are Biofol AB and Yield Life Science AB.
Employees
6
Date Price Change Volume
26-07-10 SEK 0.8250 +6.45% 405,390
26-07-09 SEK 0.7750 -8.72% 947,706
26-07-08 SEK 0.8490 +2.29% 3,183,028
26-07-07 SEK 0.8300 +0.24% 1,075,219
26-07-06 SEK 0.8280 +2.22% 952,753
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ISOFOL Stock